Cargando…

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma

Lenalidomide (also known as Revlimid(®), CC-5013) is an immunomodulatory derivative of thalidomide and has more potent anti-tumor and anti-inflammatory effects than thalidomide. The molecular mechanisms of anti-tumor activity of lenalidomide have been extensively studied in multiple myeloma (MM) bot...

Descripción completa

Detalles Bibliográficos
Autores principales: Hideshima, Teru, Raje, Noopur, Richardson, Paul G, Anderson, Kenneth C
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503648/
https://www.ncbi.nlm.nih.gov/pubmed/18728702
_version_ 1782158331077459968
author Hideshima, Teru
Raje, Noopur
Richardson, Paul G
Anderson, Kenneth C
author_facet Hideshima, Teru
Raje, Noopur
Richardson, Paul G
Anderson, Kenneth C
author_sort Hideshima, Teru
collection PubMed
description Lenalidomide (also known as Revlimid(®), CC-5013) is an immunomodulatory derivative of thalidomide and has more potent anti-tumor and anti-inflammatory effects than thalidomide. The molecular mechanisms of anti-tumor activity of lenalidomide have been extensively studied in multiple myeloma (MM) both preclinical models and in clinical trials. Lenalidomide: directly triggers growth arrest and/or apoptosis of drug resistant MM cells; inhibits binding of MM cells to bone marrow (BM) extracellular matrix proteins and stromal cells; modulates cytokine secretion and inhibits angiogenesis in the BM milieu; and augments host anti-tumor immunity. Lenalidomide achieved responses in patients with relapsed refractory MM. Moreover, lenalidomide with dexamethasone (Dex) demonstrates more potent anti-MM activities than Dex both in vitro and in randomized phase III clinical trials. Specifically, the combination improved overall and extent of response, as well as prolonged time to progression and overall survival, resulting in FDA approval of lenalidomide with Dex for therapy MM relapsing after prior therapy.
format Text
id pubmed-2503648
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-25036482008-08-26 A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma Hideshima, Teru Raje, Noopur Richardson, Paul G Anderson, Kenneth C Ther Clin Risk Manag Review Lenalidomide (also known as Revlimid(®), CC-5013) is an immunomodulatory derivative of thalidomide and has more potent anti-tumor and anti-inflammatory effects than thalidomide. The molecular mechanisms of anti-tumor activity of lenalidomide have been extensively studied in multiple myeloma (MM) both preclinical models and in clinical trials. Lenalidomide: directly triggers growth arrest and/or apoptosis of drug resistant MM cells; inhibits binding of MM cells to bone marrow (BM) extracellular matrix proteins and stromal cells; modulates cytokine secretion and inhibits angiogenesis in the BM milieu; and augments host anti-tumor immunity. Lenalidomide achieved responses in patients with relapsed refractory MM. Moreover, lenalidomide with dexamethasone (Dex) demonstrates more potent anti-MM activities than Dex both in vitro and in randomized phase III clinical trials. Specifically, the combination improved overall and extent of response, as well as prolonged time to progression and overall survival, resulting in FDA approval of lenalidomide with Dex for therapy MM relapsing after prior therapy. Dove Medical Press 2008-02 2008-02 /pmc/articles/PMC2503648/ /pubmed/18728702 Text en © 2008 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Hideshima, Teru
Raje, Noopur
Richardson, Paul G
Anderson, Kenneth C
A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
title A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
title_full A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
title_fullStr A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
title_full_unstemmed A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
title_short A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
title_sort review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503648/
https://www.ncbi.nlm.nih.gov/pubmed/18728702
work_keys_str_mv AT hideshimateru areviewoflenalidomideincombinationwithdexamethasoneforthetreatmentofmultiplemyeloma
AT rajenoopur areviewoflenalidomideincombinationwithdexamethasoneforthetreatmentofmultiplemyeloma
AT richardsonpaulg areviewoflenalidomideincombinationwithdexamethasoneforthetreatmentofmultiplemyeloma
AT andersonkennethc areviewoflenalidomideincombinationwithdexamethasoneforthetreatmentofmultiplemyeloma
AT hideshimateru reviewoflenalidomideincombinationwithdexamethasoneforthetreatmentofmultiplemyeloma
AT rajenoopur reviewoflenalidomideincombinationwithdexamethasoneforthetreatmentofmultiplemyeloma
AT richardsonpaulg reviewoflenalidomideincombinationwithdexamethasoneforthetreatmentofmultiplemyeloma
AT andersonkennethc reviewoflenalidomideincombinationwithdexamethasoneforthetreatmentofmultiplemyeloma